Systemic Infusion of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Peritoneal Dialysis Patients: Feasibility and Safety.

Authors:
Sudabeh Alatab
Sudabeh Alatab
Tehran University of Medical Sciences
Iran
Iraj Najafi
Iraj Najafi
Tehran University of Medical Sciences
Iran
Reza Moghadasali
Reza Moghadasali
Royan Institute for Stem Cell Biology and Technology
Naser Ahmadbeigi
Naser Ahmadbeigi
Tarbiat Modares University
Iran
Mohammad Reza Pourmand
Mohammad Reza Pourmand
Tehran University of Medical Sciences
Iran
Tina Bolurieh
Tina Bolurieh
Cell Science Research Center
Neda Jaroughi
Neda Jaroughi
Cell Science Research Center

Cell J 2019 Jan 12;20(4):483-495. Epub 2018 Dec 12.

Department of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Electronic address:

Objective: Using mesenchymal stem cells (MSCs) is regarded as a new therapeutic approach for improving fibrotic diseases. the aim of this study to evaluate the feasibility and safety of systemic infusion of autologous adipose tissue-derived MSCs (AD-MSCs) in peritoneal dialysis (PD) patients with expected peritoneal fibrosis.

Materials And Methods: This study was a prospective, open-label, non-randomized, placebo-free, phase I clinical trial. Case group consisted of nine eligible renal failure patients with more than two years of history of being on PD. Autologous AD-MSCs were obtained through lipoaspiration and expanded under good manufacturing practice conditions. Patients received 1.2 ± 0.1×106 cell/kg of AD-MSCs via cubital vein and then were followed for six months at time points of baseline, and then 3 weeks, 6 weeks, 12 weeks, 16 weeks and 24 weeks after infusion. Clinical, biochemical and peritoneal equilibration test (PET) were performed to assess the safety and probable change in peritoneal solute transport parameters.

Results: No serious adverse events and no catheter-related complications were found in the participants. 14 minor reported adverse events were self-limited or subsided after supportive treatment. One patient developed an episode of peritonitis and another patient experienced exit site infection, which did not appear to be related to the procedure. A significant decrease in the rate of solute transport across peritoneal membrane was detected by PET (D/P cr=0.77 vs. 0.73, P=0.02).

Conclusion: This study, for the first time, showed the feasibility and safety of AD-MSCs in PD patients and the potentials for positive changes in solute transport. Further studies with larger samples, longer follow-up, and randomized blind control groups to elucidate the most effective route, frequency and dose of MSCs administration, are necessary (Registration Number: IRCT2015052415841N2).

Download full-text PDF

Source
http://celljournal.org/journal/article/abstract/5591
Publisher Site
http://dx.doi.org/10.22074/cellj.2019.5591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099152PMC
January 2019
20 Reads

Publication Analysis

Top Keywords

weeks weeks
16
solute transport
12
feasibility safety
12
dialysis patients
8
stem cells
8
peritoneal dialysis
8
mesenchymal stem
8
adipose tissue-derived
8
systemic infusion
8
infusion autologous
8
autologous adipose
8
adverse events
8
peritoneal
6
weeks
5
patients
5
clinical biochemical
4
weeks infusion
4
points baseline
4
baseline weeks
4
biochemical peritoneal
4

Similar Publications